Johnson & Johnson (NYSE:JNJ) subsidiary Biosense Webster said last Thursday that it launched the Carto 3 system Confidense 3D cardiac mapping module for use during catheter ablation procedures.
The module uses a proprietary algorithm to speed up the process of multi-electrode cardiac mapping, the company said, streamlining a validation process that previously had to be done manually.
“While high-density maps generated through multi-electrode mapping provide the most comprehensive and accurate image of the cardiac structures, this process can prove to be time intensive. The new Confidense Module streamlines the mapping and validation process, which has the potential to reduce overall mapping, annotation and re-annotation time. I’m pleased that continued innovation in this space is enabling us to realize important clinical efficiencies while preserving the critical data and accuracy we have come to rely on from the Carto System,” Dr. Vias Markides, director of London’s Royal Brompton Hospital’s heart division, said in a press release.
The Confidense system also provides real-time assessments of catheter electrode proximity to heart tissue, enhances the consistency of data acquisition and identifies inconsistent points and brings them to the physician’s attention, the company said.
“We are committed to collaborating closely with the clinical community to introduce novel innovations that not only enable access to the most accurate and comprehensive mapping data available, but in making the acquisition of this data fast, simpler and more intuitive for users. We are excited to introduce this latest innovation for our foundational Carto System platform, a fully integrated system that delivers the most comprehensive suite of solutions for physicians worldwide,” Biosense Webster U.S. president David Shepherd said in prepared remarks.
The Confidense module has CE Mark approval in the European Union and has won FDA 510(k) approval in the U.S., the company said. U.S. availability is slated for July.
